The American Depositary Receipts and US-listed debt securities are expected to commence trading on Nasdaq from September 25, keeping the same ticket symbol ‘AZN’.
The primary listing in the UK and in Sweden are unaffected by the move.
“As a global science-led, patient-focused biopharmaceutical company, dedicated to pushing the boundaries of science to deliver life-changing medicines, we are excited to be joining many of the world's largest and most innovative companies on Nasdaq,” said Marc Dunoyer, executive director and chief financial officer.
Good results for rhinosinusitis candidate
In a separate announcement, the FTSE 100 pharma giant revealed its candidate Fasenra showed “high-level” results in a phase III trial for patients with chronic rhinosinusitis with nasal polyps.
The antibody demonstrated a statistically significant improvement in two scores compared to placebo.
Chronic rhinosinusitis with nasal polyps is an inflammatory disease comprising benign growths across the nose and throat, which can cause blockage and discharge, reduction or loss in the sense of smell and sleep issues.
Fasenra is currently approved as an add-on maintenance treatment for severe eosinophilic asthma in the US, EU, Japan and other countries and is approved for self-administration in the US, EU and other countries.